Table 2.
COX proportional regression analysis associated with all-cause mortality.
| Univariate cox regression |
Multivariate cox regression |
|||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p value | HR | 95%CI | p value | |
| Anemia | 1.74 | 1.33–2.28 | <0.001 | 1.14 | 0.85–1.52 | 0.386 |
| RD | 1.76 | 1.36–2.29 | <0.001 | 1.18 | 0.88–1.57 | 0.269 |
| Age | 1.07 | 1.05–1.08 | <0.001 | 1.05 | 1.03–1.07 | <0.001 |
| Heart rate | 1.01 | 1.00–1.02 | 0.006 | 1.01 | 0.99–1.01 | 0.117 |
| Serum sodium | 0.99 | 0.98–1.00 | 0.003 | 0.98 | 0.97–0.99 | 0.001 |
| Serum potassium | 1.40 | 1.13–1.74 | 0.002 | 1.22 | 0.98–1.52 | 0.071 |
| TC | 0.90 | 0.80–1.01 | 0.062 | 0.99 | 0.90–1.09 | 0.860 |
| HDL | 1.40 | 1.21–1.63 | <0.001 | 1.34 | 1.11–1.61 | 0.002 |
| LDL | 0.84 | 0.72–0.98 | 0.028 | 0.90 | 0.75–1.07 | 0.220 |
| TG | 0.62 | 0.50–0.78 | <0.001 | 0.82 | 0.66–1.01 | 0.060 |
| NYHA class | 1.80 | 1.50–2.16 | <0.001 | 1.42 | 1.15–1.74 | 0.001 |
| BNP > 400 ng/l or NT-proBNP > 1500 ng/l | 2.05 | 1.57–2.67 | <0.001 | 1.26 | 0.93–1.70 | 0.131 |
| ACEI/ARB | 0.71 | 0.54–0.94 | 0.018 | 0.81 | 0.61–1.08 | 0.144 |
| Digital | 1.68 | 1.28–2.20 | <0.001 | 1.27 | 0.94–1.72 | 0.121 |
| MRA | 1.76 | 1.28–2.42 | 0.001 | 0.98 | 0.69–1.39 | 0.887 |
| Stain | 0.74 | 0.57–0.96 | 0.024 | 1.01 | 0.75–1.36 | 0.966 |
| Aspirin | 0.78 | 0.60–1.02 | 0.067 | 1.05 | 0.78–1.40 | 0.765 |
RD, renal dysfunction; TC, serum total cholesterol; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; TG, triglyceride; NYHA, New York Heart Association; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; MRA, mineralocorticoid receptor antagonist.